Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G. Kaufmann M, et al. Among authors: mennel rg. J Clin Oncol. 2000 Apr;18(7):1399-411. doi: 10.1200/JCO.2000.18.7.1399. J Clin Oncol. 2000. PMID: 10735887 Clinical Trial.
Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study.
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G. Kaufmann M, et al. Among authors: mennel rg. Clin Breast Cancer. 2000 Sep;1 Suppl 1:S15-8. doi: 10.3816/cbc.2000.s.003. Clin Breast Cancer. 2000. PMID: 11970744 Clinical Trial.
Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, George TK, Snyder DA, Watkins DL, Denham CA, Hoyes FA, Rubin AS. Jones SE, et al. Among authors: mennel rg. J Clin Oncol. 1996 Nov;14(11):2976-83. doi: 10.1200/JCO.1996.14.11.2976. J Clin Oncol. 1996. PMID: 8918495 Clinical Trial.
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN, Burris HA 3rd. Valero V, et al. Among authors: mennel rg. J Clin Oncol. 1998 Oct;16(10):3362-8. doi: 10.1200/JCO.1998.16.10.3362. J Clin Oncol. 1998. PMID: 9779713 Clinical Trial.
Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer.
Jones SE, Khandelwal P, McIntyre K, Mennel R, Orr D, Kirby R, Agura E, Duncan L, Hyman W, Roque T, Regan D, Schuster M, Dimitrov N, Garrison L, Lange M. Jones SE, et al. J Clin Oncol. 1999 Oct;17(10):3025-32. doi: 10.1200/JCO.1999.17.10.3025. J Clin Oncol. 1999. PMID: 10506596 Clinical Trial.
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tendler C. Keller AM, et al. Among authors: mennel rg. J Clin Oncol. 2004 Oct 1;22(19):3893-901. doi: 10.1200/JCO.2004.08.157. J Clin Oncol. 2004. PMID: 15459210 Clinical Trial.
47 results